Accessibility Menu
 
Avalo Therapeutics logo

Avalo Therapeutics

(NASDAQ) AVTX

Current Price$13.90
Market Cap$258.25M
Since IPO (2015)-100%
5 Year-100%
1 Year+67%
1 Month-14%

Avalo Therapeutics Financials at a Glance

Market Cap

$258.25M

Revenue (TTM)

$59.00K

Net Income (TTM)

$78.26M

EPS (TTM)

$-6.10

P/E Ratio

-2.29

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$13.90

Volume

355,132.908

Open

$13.80

Previous Close

$13.95

Daily Range

$13.49 - $14.02

52-Week Range

$3.39 - $20.72

AVTX News

No articles available.

AVTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avalo Therapeutics

Industry

Biotechnology

Employees

33

CEO

Garry Arthur Neil, MD

Headquarters

Rockville, MD 20850, US

AVTX Financials

Key Financial Metrics (TTM)

Gross Margin

73%

Operating Margin

-1236%

Net Income Margin

-1326%

Return on Equity

-72%

Return on Capital

-70%

Return on Assets

-67%

Earnings Yield

-43.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$258.25M

Shares Outstanding

18.51M

Volume

355.13K

Short Interest

0.00%

Avg. Volume

523.50K

Financials (TTM)

Gross Profit

$285.00K

Operating Income

$72.92M

EBITDA

$72.92M

Operating Cash Flow

$51.46M

Capital Expenditure

$0.00

Free Cash Flow

$51.46M

Cash & ST Invst.

$98.34M

Total Debt

$2.43M

Avalo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$59.00K

-69.3%

Gross Profit

$43.00K

-59.0%

Gross Margin

72.88%

N/A

Market Cap

$258.25M

N/A

Market Cap/Employee

$11.23M

N/A

Employees

23

N/A

Net Income

$13.72M

+61.2%

EBITDA

$19.73M

-49.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$95.91M

-28.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$2.04M

N/A

Short Term Debt

$392.00K

-31.0%

Return on Assets

-67.20%

N/A

Return on Invested Capital

-70.45%

N/A

Free Cash Flow

$14.25M

+5.3%

Operating Cash Flow

$14.25M

+5.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OBIOOrchestra BioMed Holdings, Inc.
$4.25-5.35%
ENTAEnanta Pharmaceuticals, Inc.
$12.17-2.68%
EPRXEupraxia Pharmaceuticals Inc.
$6.75-1.46%
IVAInventiva S.A.
$5.75-5.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.27+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$38.92-0.06%
ARTLArtelo Biosciences
$11.29+2.54%
QQQInvesco QQQ Trust
$563.24-0.02%

Questions About AVTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.